Coherus Shelves Eylea Biosimilar And Rules Out Early-Stage Biosimilar Development
Biosimilars Leader Coherus Marks New Era With Immuno-Oncology Play
Coherus BioSciences, a leader and innovator in the nascent US biosimilars space, has announced plans to ditch a key biosimilar opportunity and limit overall investment, in order to direct resources to immuno-oncology.
You may also be interested in...
Coherus BioSciences aims to have four biosimilars on the market by 2023, including ranibizumab and bevacizumab for which it has provided updated timelines for planned US Food and Drug Administration filings.
Coherus BioSciences has had its say on the prospect of interchangeability for Humira biosimilars, shortly after Boehringer Ingelheim announced positive data from a ‘first-of-its-kind’ switching study.
Sandoz has revealed late-stage clinical development plans for an aflibercept biosimilar, setting out details of a Phase III trial for the proposed Eylea rival.